MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

Author's Avatar
Jan 11, 2023

HALIFAX, NS / ACCESSWIRE / January 11, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR, Financial) announces the receipt of the CE mark for its VYRA™ CoV2Flu Antigen Test (VYRA™ CoV2Flu), the fastest combination antigen test available to detect SARS-CoV-2, Flu A and Flu B. The Company received the CE mark and VYRA™ CoV2Flu is now available in Europe and any countries accepting the CE mark.